Last reviewed · How we verify

Shenzhen TargetRx Co., Ltd. — Portfolio Competitive Intelligence Brief

Shenzhen TargetRx Co., Ltd. pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 10 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
TGRX-678 TGRX-678 phase 3 SGLT2 inhibitor SGLT2 Diabetes
TGRX-326 TGRX-326 phase 3 SGLT2 inhibitor SGLT2 Diabetes
TKI TKI phase 3 Tyrosine kinase inhibitor Tyrosine kinases (e.g. EGFR, HER2, BCR-ABL) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 2 shared drug classes
  2. Pfizer · 2 shared drug classes
  3. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes
  4. ADvantage Therapeutics · 1 shared drug class
  5. Abbott · 1 shared drug class
  6. AceLink Therapeutics, Inc. · 1 shared drug class
  7. AO GENERIUM · 1 shared drug class
  8. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shenzhen TargetRx Co., Ltd.:

Cite this brief

Drug Landscape (2026). Shenzhen TargetRx Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shenzhen-targetrx-co-ltd. Accessed 2026-05-16.

Related